Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)
Salbutamol sulfate
Approved Prescription Services Ltd
R03CC02
Salbutamol sulfate
2mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 03010101
10mm text free to right of pharmacode 10mm text free to left of pharmacode Pharmacode Area (12 x 20mm) 10mm Bleed off by 2mm at bottom of page 30x115mm 18pp label leaflet Profile (BST) BATCH & 2D CODING AREA PRINT FREE DO NOT REMOVE THIS PANEL * Please note that ONLY Artwork Studio is permitted to make changes to the above artwork. No changes are permitted by any 3rd party other than added notes and mark ups for required changes. approved for print/date PROOF ROUND UK-Eire-Artwork-Support@accord-healthcare.com Technical Approval NON PRINTING COLOURS COLOURS DATE SENT: DATE RECEIVED: Item number: ORIGINATOR: ORIGINATION DATE: REVISION DATE: REVISED BY: DIMENSIONS: MIN BODY TEXT SIZE: SUPPLIER: 1. 2. 3. 4. 5. 6. 1. 2. 3. 4. 5. FMD info NA (not a carton) No Yes Details ________________________________________________________________________________________ Version 2 01.11.2017 SALBUTAMOL 2MG 28 TABLETS LABEL LEAFLET - UK 04 Black R.Paul 25.07.2019 06-08-19 RH BBBA5633 30 x 115 7pts Accord Barnstaple n/a n/a Profile Braille Print Free Areas FMD PRINT FREE Print free areas required for FMD. PRINT FREE AREAS 50973994 BBBA5633 50973994 BBBA5633 5 0 1 2 6 1 7 0 0 8 9 2 3 TABLETS SALBUTAMOL 2 MG _28 TABLETS_ _For oral use_ Each tablet contains 2.4mg salbutamol sulfate equivalent to2mg salbutamol. For oral administration. Also contains lactose, E122-see leaflet for details. Use as directed by physician. Keep out of the sight and reach of children. Read the package leaflet before use. Store below 25°C in a dry place. PL 0142/0485 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any pos Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Salbutamol Tablets BP 2mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.4mg salbutamol sulfate equivalent to 2mg salbutamol. Excipients with known effect: Each 2mg tablet contains: - 60.05mg Lactose monohydrate - Carmoisine (E122) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets for oral administration. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Salbutamol Tablets are indicated in adults, adolescents and children aged 2 to 12 years. 1. For the relief of bronchospasm in bronchial asthmas of all types. 2. Chronic bronchitis. 3. Emphysema. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults:_ The usual effective dose is 4mg three or four times per day. If adequate bronchodilation is not obtained each single dose may be gradually increased to as much as 8mg. However, it has been established that some patients obtain adequate relief with 2mg three or four times daily. In elderly patients or in those known to be unusually sensitive to beta-adrenergic stimulant drugs, it is advisable to initiate treatment with 2mg three or four times per day. _ _ _Children:_ The following doses should be administered three or four times daily. 2-6 years: 1-2mg 6-12 years: 2mg Over 12 years: 2-4mg The product is not recommended for children under 2 years of age. The drug is well tolerated by children so that, if necessary, these doses may be cautiously increased. Method of administration For oral use. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Salbutamol should not be used for threatened abortion during the first or second trimester of pregnancy. Salbutamol and beta-blocking drugs such as propranolol should not usually be prescribed together. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Increasing use of bronchodilators in particular s Izlasiet visu dokumentu